Logo of amjpatholAmerican Journal of Pathology For AuthorsAmerican Journal of Pathology SubscribeAmerican Journal of Pathology SearchAmerican Journal of Pathology Current IssueAmerican Journal of Pathology About the JournalAmerican Journal of Pathology
Am J Pathol. 2001 May; 158(5): 1743–1756.
PMCID: PMC1891960

Systemic Infusion of Angiotensin II into Normal Rats Activates Nuclear Factor-κB and AP-1 in the Kidney

Role of AT1 and AT2 Receptors


Recent studies have pointed out the implication of angiotensin II (Ang II) in various pathological settings. However, the molecular mechanisms and the AngII receptor (AT) subtypes involved are not fully identified. We investigated whether AngII elicited the in vivo activation of nuclear transcription factors that play important roles in the pathogenesis of renal and vascular injury. Systemic infusion of Ang II into normal rats increased renal nuclear factor (NF)-κB and AP-1 binding activity that was associated with inflammatory cell infiltration and tubular damage. Interestingly, infiltrating cells presented activated NF-κB complexes, suggesting the involvement of AngII in inflammatory cell activation. When rats were treated with AT1 or AT2 receptor antagonists different responses were observed. The AT1 antagonist diminished NF-κB activity in glomerular and tubular cells and abolished AP-1 in renal cells, improved tubular damage and normalized the arterial blood pressure. The AT2 antagonist diminished mononuclear cell infiltration and NF-κB activity in glomerular and inflammatory cells, without any effect on AP-1 and blood pressure. These data suggest that AT1 mainly mediates tubular injury via AP-1/NF-κB, whereas AT2 receptor participates in the inflammatory cell infiltration in the kidney by NF-κB. Our results provide novel information on AngII receptor signaling and support the recent view of Ang II as a proinflammatory modulator.

Angiotensin II (AngII), the main effector peptide of the renin-angiotensin system (RAS), plays a central role in the pathophysiology of cardiovascular and renal diseases and in the etiology of hypertension in humans. This vasoactive peptide is now considered to be a growth factor that participates in the regulation of cell growth and gene expression of various bioactive substances (ie, extracellular matrix components, growth factors, cytokines, chemokines). 1-4 Some studies have investigated the in vivo effects of systemic AngII infusion in the kidney, showing proliferation of renal cells, tubular atrophy, accumulation of extracellular matrix proteins (fibronectin and collagens), 5-7 and induction of growth factors, such as transforming growth factor-β (TGF-β). 8 Another feature of AngII-induced kidney damage is the presence of infiltrating inflammatory cells. 5,9 However, the molecular mechanisms of AngII action in this setting still remain unclear.

Transcription factors are important mediators involved in signal transduction that bind to specific DNA sequences in gene promoters, and regulate transcriptional activity. In cultured cells, AngII activates various nuclear transcription factors, including the activator protein-1 (AP-1), 10 STAT family of transcription factors, 11 cyclic adenosine monophosphate response element binding protein 12 and, as we have previously shown, nuclear factor-κB (NF-κB). 3,13 Emerging attention has been focused on the regulation and function of transcription factors, such as NF-κB and AP-1 during tissue injury. 14,15 NF-κB has special interest because it plays a pivotal role in the control of several genes, including cytokines, chemokines, adhesion molecules, NO synthase, and angiotensinogen, involved in the pathogenesis of inflammatory lesions, kidney damage, and hypertension. 14 In several models of renal damage, an elevated tissular NF-κB DNA binding activity that diminished in response to angiotensin-converting enzyme (ACE) inhibition has been found. 3,16 In other pathological conditions associated with activated RAS, such as atherosclerosis, the increased tissular NF-κB activity was also found to decrease by ACE inhibition. 13 Double-transgenic rats overexpressing both renin and angiotensinogen genes exhibited increased NF-κB activity in the heart and kidney. In these animals, the antioxidant pyrrolidine dithiocarbamate inhibits NF-κB, ameliorates inflammation, and protects against AngII-induced end-organ damage. 17 However, the in vivo effect of AngII on NF-κB activation, and the potential receptor subtype involved, have not been elucidated.

Two pharmacologically distinct subclasses of AngII receptors (AT1 and AT2) have been described. 18,19 The well-known AngII actions, such as the regulation of blood pressure and water-electrolyte balance, and growth-promoting effects, have been attributed mainly to the activation of various signal-transduction pathways via AT1. 18,19 AT1 antagonists are currently used to treat patients with hypertension or heart failure. Treatment with AT1 antagonists causes elevation of plasma AngII, which selectively binds to AT2 and theoretically could exert clinically important, but yet undefined, effects. 20 The biological functions and the signal transduction pathway of AT2 are primarily unknown. AT2 regulates cell growth inhibition, blood pressure, diuresis/natriuresis, renal NO production and glomerular monocyte infiltration. 9,21,22 The AT2 mRNA is highly expressed in the fetal kidney, in lower levels in the adult, and is re-expressed in pathological situations involving tissue remodeling or inflammation, such as neointima formation, heart failure, and wound healing. 21,23,24 Renal AT2 may be activated during sodium depletion or AngII administration in the rat. 21,25 Therefore, understanding of AT2-mediated physiopathological actions may have important pharmacological implications.

To elucidate the molecular mechanisms implicated in the AngII-induced kidney damage we have investigated the renal activity of the transcription factors NF-κB and AP-1, related to the pathological effects caused by systemic infusion of AngII, such as inflammatory cell infiltration and tubular damage. We have also determined the receptor subtype associated with these effects by using the specific receptor antagonists, losartan for AT1 and PD123319 for AT2.

Materials and Methods

Experimental Design

The in vivo effect of AngII was evaluated by systemic infusion of AngII (dissolved in saline) into female Wistar rats (subcutaneously by osmotic minipumps; Alza Corp., Palo Alto, CA), at the dose of 50 ng/kg/minute. Animals were sacrificed at 24, 48, and 72 hours (acute study), and at 7 days (chronic study). Then, tissue samples were immediately removed and further processed for histological studies and protein extraction. To determine the role of AngII receptor, a group of rats was treated with the AT1 antagonist losartan (10 mg/kg/day in the drinking water) or the AT2 antagonist PD123319 (30 mg/kg/day, subcutaneously by osmotic minipumps) from 24 hours before AngII infusion, and after an additional 72 hours. Losartan was kindly provided by MSD (Spain), and PD123319 was from Sigma (St. Louis, MO). The doses of losartan and PD123319 have previously demonstrated to cause an effective blockade of AT1 and AT2, respectively. 26-29 Control groups of animals of the same age, untreated or treated (AT antagonists and saline-infused), were also studied. Systolic arterial blood pressure was measured in conscious, restrained rats by the tail-cuff sphygmomanometer (NARCO Biosystems, CO). The blood pressure value for each rat was calculated as the average of three separate measurements at each session.

Cell Cultures

The murine tubuloepithelial cells (MCT cell line) were kindly donated by Dr. E. Neilson (University of Pennsylvania). The human monocytic cell line U937 (1593-CRL) was obtained from the American Type Culture Collection (Rockville, MD). U937 cells were grown in suspension and 5 × 10 6 cells were used in each experiment. These cell lines were cultured in RPMI medium with 10% fetal calf serum (FCS) (Gibco BRL, Paisley, Scotland, UK).

Analysis of Transcription Factor Activity

NF-κB and AP-1 activity was evaluated by binding of 10 μg of protein extracts from renal cortex or cells with an oligoconsensus NF-κB or AP-1 labeled with [γ-32P]-ATP and the complexes formed were analyzed by electrophoretic mobility shift assay (EMSA). Protein extraction were done as described. 3 Growth-arrested MCT were incubated with AngII (10−7, 10−9 and 10−11 mol/L) for 30, 60, and 120 minutes. As positive controls, 100 U/mL of tumor necrosis factor-α and 10−7 mol/L phorbol myristate acetate were used. For in vivo studies, frozen kidney pieces were pulverized in a metallic chamber and resuspended in a cold extraction buffer [20 mmol/L HEPES-NaOH (pH 7.6), 20% (vol/vol) glycerol, 0.35 mol/L NaCl, 5 mmol/L MgCl2, 0.1 mmol/L ethylenediaminetetraacetic acid (EDTA), 1 mmol/L dithiothreitol, 0.5 mmol/L phenylmethyl sulfonyl fluoride (PMSF), 1 mg/L pepstatin A]. The homogenate was vigorously shaken for 30 minutes, and the insoluble materials precipitated by centrifugation at 40,000 × g for 30 minutes at 4°C. For in vitro studies, cells were resuspended in extraction buffer (10 mmol/L HEPES, pH 7.8, 15 mmol/L KCl, 2 mmol/L MgCl2, 0.1 mmol/L EDTA, 1 mmol/L dithiothreitol, 1 mmol/L PMSF) and homogenized. Nuclei and cytosolic fractions were separated by centrifugation at 1000 × g for 10 minutes, the nuclei were resuspended in extraction buffer to a final concentration of 0.39 mol/L KCl, and centrifuged at 100,000 × g for 30 minutes. Supernatants dialyzed overnight against a binding buffer containing 20 mmol/L HEPES-NaOH (pH 7.6), 20% (v/v) glycerol, 0.1 mmol/L NaCl, 5 mmol/L MgCl2, 0.1 mmol/L EDTA, 1 mmol/L dithiothreitol, and 0.5 mmol/L PMSF. The dialysates were cleared by centrifugation at 10,000 × g for 15 minutes at 4°C and frozen at −80°C. Protein concentration was quantified by the bicinchoninic acid method (Pierce, Rockford, IL).

NF-κB and AP-1 consensus oligonucleotides (5′-AGTTGAGGGGACTTTCCCAGGC-3′ and 5′-CGCTTGATGAGTCAGCCGGAA-3′, respectively) were end-labeled with [γ-32P]ATP (Amersham, Buckinghamshire, UK) and T4 polynucleotide kinase (Promega). Nuclear extracts were equilibrated for 10 minutes in a binding buffer [4% glycerol, 1 mmol/L MgCl2, 0.5 mmol/L EDTA, 0.5 mmol/L dithiothreitol, 50 mmol/L NaCl, 10 mmol/L Tris-HCl, pH 7.5, and 50 μg/ml of poly(dI-dC)] (Pharmacia LKB, Uppsala, Sweden), then the labeled probe (0.35 pmol) was added and incubated for 20 minutes at room temperature. Negative controls without cellular extracts, and competition assays with a 100-fold excess of unlabeled NF-κB, mutant NF-κB, and AP-1 oligonucleotides, were performed to establish the specificity of the reaction. When competition assays were done, the unlabeled probe was added to this buffer 10 minutes before the addition of the labeled probe. HeLa cell nuclear extracts were used as a positive control (not shown). The antibodies to NF-κB proteins were from Santa Cruz Biotechnology Inc. (Santa Cruz, CA) and Chemikon (Temecula, CA). For supershift assays, 1 μg of anti-p50, anti-p65, or anti-c-Rel antibodies was added to protein extracts from cortex of AngII-infused rats, and incubated for 1 hour before the addition of the labeled probe. Supershift assays were also done with HeLa cell nuclear extracts. The supershift band was competed by a 100-excess of unlabeled specific (NF-κB), but not by mutant NF-κB probe (not shown). The specificity of the antibodies was confirmed by Western blot (not shown). Oligonucleotides were from Promega Corp. (Madison, WI). The reaction was stopped by adding gel-loading buffer (250 mmol/L Tris-HCL, 0.2% bromophenol blue, 0.2% xylene cyanol, and 40% glycerol) and protein-DNA complexes were separated on a nondenaturing, 4% acrylamide gel in Tris-borate. The gel was dried and exposed to X-ray film.

Determination of mRNA Expression of AT2

In kidney samples and in 48-hour serum-deprived MCT cells, AT2 mRNA expression was analyzed by reverse transcriptase-polymerase chin reaction (RT-PCR), 23 with specific primers 5′-CTGACCCTGAACATGTTTGCA-3′ (sense) and 5′-GGTGTCCATTTCTCTAAGAG-3′ (antisense), yielding a 710-bp product. PCR amplification (1 minute at 58°C, 1 minute at 68°C, and 1 minute at 94°C) was linear up to 50 cycles, and data corresponding to cycle 35 were used for calculations. Control experiments were done with RNA samples, but without avian myeloblastosis virus reverse transcriptase. The DNA products were analyzed on 1.5% agarose gel and ethidium bromide staining.

Western Blot of AngII Receptors

Total proteins were obtained from homogenized cells in lysis buffer (50 mmol/L Tris-HCl, 150 mmol/L NaCl, 2 mmol/L EDTA, 2 mmol/L EGTA, 0.2% Triton X-100, 0.3% Nonidet P-40, 0.1 mmol/L PMSF, and 1 μg/ml pepstatin A) and then separated by 12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis under reducing conditions. After electrophoresis, samples were transferred to polyvinylidene difluoride membranes (Millipore, Bedford, MA). The membranes were blocked in 0.01 mmol/L Tris, pH 7.5, and 0.4 mol/L NaCl containing 0.1% Tween-20, 1% bovine serum albumin (BSA) and 5% dry skimmed milk for 30 minutes at 37°C, and then incubated in the same buffer with a specific AT2 or AT1 antibody for 18 hours at 4°C. After washing, detection was made by incubation with peroxidase-conjugated secondary antibody, and developed using an ECL chemiluminescence kit (Amersham). Samples from rat adrenal gland were used as positive control for AT2 expression (not shown). The specificity of AT1 and AT2 antibodies was also determined by incubation with blocking peptides (not shown). The antibodies to AT1 and AT2 were from Santa Cruz, secondary horseradish peroxidase-conjugatedantibodies were from The Binding Site (Birmingham, UK), and control rabbit IgG from Sigma.

Renal Histopathological Studies

The kidney samples were studied by staining with hematoxylin/eosin and Masson’s tricrome technique, and examined by light microscopy. The inflammatory cell infiltration was evaluated by immunohistochemistry in formalin-fixed paraffin-embedded sections with an anti-rat CD43 antibody (Pharmingen). This monoclonal antibody reacts with an epitope of CD43 expressed in monocytes, macrophages, natural killer cells, and T cells. A specific monocyte/macrophage marker, an anti-rat ED1 antibody (Serotec) was also used. The presence of AT2 in renal tissue was determined by immunohistochemistry with a specific goat anti-AT2 antibody recognizing rat and human AT2 (Santa Cruz; tested by Western blot). To localize DNA-binding activity of transcription factors Southwestern histochemistry was used. 30 The quantification of the infiltrating cells was performed as previously reported. 31 The mean number of cells per glomerular cross-section was determined by evaluating 15 glomeruli and the whole interstitium from each animal. Semiquantitative determination was done for morphology, immunohistochemistry, and Southwestern, using the following score: 0, no staining; 1+, mild staining; 2+, moderate staining; 3+, marked staining. Histological studies were quantified by two independent observers in a blinded manner and the mean value was calculated for each rat.

Tissue Localization of CD43, ED-1, and AT2 Immunoreactivity

Paraffin-embedded renal tissue sections (4 μm) were mounted on poly-l-lysine-coated slides. The slides were deparaffinized with xylene and graded concentrations of ethanol and then rehydrated. The endogenous peroxidase was blocked by incubating in 3% H2O2/methanol (1:1) at 25°C for 30 minutes. The slides were subsequently incubated in phosphate-buffered saline (PBS) with 6% horse serum in 4% BSA for 1 hour at 37°C to reduce nonspecific background staining, and then incubated overnight at 4°C with anti-CD43, anti-ED1, or anti-AT2 antibodies in PBS containing 1% serum and 4% BSA. After being washed with PBS, the sections were incubated with secondary anti-IgG HRPO-conjugated antibody diluted 1:100 in 4% BSA/PBS for 30 minutes, and after washing, they were stained with 0.05% 3,3′-diaminobenzidine (DAKO, Glostrup, Denmark) in 0.3% H2O2 for 10 minutes. The sections were counterstained with Mayer’s hematoxylin and mounted in Pertex (Medite). In each experiment, negative controls without the primary antibody, or using an unrelated antibody, were included to check for nonspecific staining.

Southwestern Histochemistry

Sections of renal tissue were dehydrated, rehydrated, fixed with 0.5% paraformaldehyde and treated with 5 mmol/L levamisole for 30 minutes. Then, sections were digested with 0.5% pepsin in 1 N HCl for 30 minutes at 37°C, washed twice with buffer HEPES-BSA (10 mmol/L HEPES, 40 mmol/L NaCl, 10 mmol/L MgCl2, 1 mmol/L dithiothreitol, 1 mmol/L EDTA, 0.25% BSA), and treated with 0.1 mg/ml DNAsa I for 20 minutes. After that, samples were incubated overnight at 37°C with the NF-κB and AP-1 oligonucleotide digoxigenin-labeled at a final concentration of 100 pmol/ml in HEPES-BSA with 0.5 μg/ml of poly (dI-dC). After washing, samples were incubated with an anti-digoxigenin antibody conjugated with alkaline phosphatase (Boehringer Mannheim, Mannheim, Germany) for 1 hour at 37°C and were revealed with 0.4% 4-nitroblue tetrazolium chloride and 0.32% X-phosphate. The reaction was stopped with 10 mmol/L Tris, pH 8, 1 mmol/L EDTA. Preparations were mounted with glycerol. Synthetic consensus sense (NF-κB: 5′-AGTTGAGGGGACTTTCCCAGGC-3′; AP-1: 5′-CGCTTGATGAGTCAGCCGGAA-3′), and mutant sense (NF-κB: 5′-AGTTAGCGCTCCTTTCCCAGGC-3′; AP-1: 5′-CGCTTGATAAATCAGCCGGAA-3′) probes (Genosys Biotechnology,London, UK). Double-stranded DNA probes were labeled with digoxigenin (DIG oligonucleotide 3′end labeling, Boehringer). Preparations without probe were used as negative controls, and mutant probes were used to test the specificity of the technique.

Statistical Analysis

Results are expressed as the mean ± SEM. Significance was established using t-test and analysis of variance when appropriate. Differences were considered significant if P < 0.05.


Role of AT1 and AT2 Receptors in AngII-Induced Renal Damage

Systemic infusion of AngII (50 ng/kg/min, subcutaneously by osmotic minipumps) caused a slight increase in systolic blood pressure after 72 hours (121 ± 9 versus 100 ± 2 mmHg in controls, n = 10, P < 0.05), but within the normotensive range. Morphological lesions were examined by light microscopy. After 72 hours of AngII infusion, the majority of the glomeruli had a normal appearance. Interstitial inflammatory cell infiltration and mild tubular lesions were observed (Figure 1) [triangle] . The inflammatory cell infiltration was further examined by immunohistochemistry with a specific anti-CD43 antibody (Figure 2) [triangle] . In control animals, only few cells with positive anti-CD43 immunostaining were observed (Figure 2; A, C, E, and I [triangle] ). AngII-infused animals had some inflammatory cells in the glomeruli (Figure 2; B, F, and M [triangle] ). An important increase in the mean number of inflammatory cells expressing CD43 antigen was observed in the interstitium, distributed in a focal manner (Figure 2; D, J, and M [triangle] ). Some of these cells were monocytes/macrophages, as determined with an anti-rat ED1 antibody (data not shown). Our findings are similar to that observed with low doses of AngII infusion, that also showed a slight increase in blood pressure, glomerular monocyte infiltration, and fibrosis. 6,9 The animals treated with AngII (50 ng/kg/minute) for 7 days showed marked tubular injury (data not shown). In this sense, AngII infusion for 14 days, although at higher doses (200 ng/kg/min), resulted in moderate systolic hypertension associated with cell proliferation, fibrosis, and tubulointerstitial damage. 5,6

Figure 1.
Glomerular and interstitial morphology after systemic infusion of AngII. Animals were pretreated for 24 hours with the AT antagonists losartan (AT1, 10 mg/kg/day in drinking water) and PD123319 (AT2, 30 mg/kg/day, s.c.), and then infused with AngII for ...
Figure 2.
AngII infusion increases inflammatory cell infiltration in the kidney. [triangle] shows glomerular (A and B) and tubulointerstitial (C and D) areas of a representative animal of control (A and C) and AngII-infused (B and D) groups. Original magnification, ...

In 72-hour AngII-infused rats, losartan administration (AT1 antagonist; 10 mg/kg/day) abolished the increase in blood pressure induced by AngII (99 ± 2 mmHg, n = 6, P < 0.05 versus AngII). AngII-infused rats that received a simultaneous infusion of PD123319 (AT2 antagonist; 30 mg/kg/day) showed a rise in blood pressure similar to that of rats receiving only AngII (123 ± 16 mmHg, n = 4; P = ns versus AngII; P < 0.05 versus controls). Losartan or PD123319 alone had no effect on blood pressure (not shown). Some differences were observed between the effect of AT1 and AT2 antagonists in AngII-induced renal lesions. The AT1 antagonist ameliorated tubular atrophy (Figure 1C) [triangle] , whereas the AT2 antagonist diminished inflammatory cell infiltration (Figure 1D) [triangle] , presenting a marked reduction in CD43-positive cells both in glomerular and interstitial areas (Figure 2, H, L, and M) [triangle] . PD123319 also diminished glomerular ED-1-positive cells (monocytes/macrophages) (data not shown), as previously described. 9

AngII Infusion Activates NF-κB in the Kidney

AngII infusion increased renal NF-κB DNA-binding activity, beginning at 24 hours, peaking at 72 hours (6.5-fold versus control, n = 10, P < 0.05), and declining at 7 days, but without reaching control values (3.7-fold, n = 8, P < 0.05 versus control) (Figure 3) [triangle] . Renal NF-κB activity in saline-infused rats showed no difference versus that in healthy control rats (n = 6, P = ns, Figure 3A [triangle] ). The signal of the retarded bands was only decreased with an excess of unlabeled NF-κB, but not mutant NF-κB or AP-1 (unrelated nuclear protein binding), showing the specificity of the binding (Figure 3B) [triangle] . To characterize the nuclear protein binding to the NF-κB motif, protein extracts from AngII-infused rats were preincubated with antibodies against the NF-κB subunits, p50, p65, and c-rel. 14 In the presence of anti-p50 and anti-p65 antibodies a supershifted band appeared, whereas there was no changes in the intensity of the complexes (Figure 3, C and D) [triangle] . None of the complexes were inhibited by the antibody against c-Rel (Figure 3, C and D) [triangle] , thus this subunit does not seem to be present in AngII-induced NF-κB complexes, as observed in mesangial cells. 3 These results suggest that in AngII-infused rats the activated NF-κB complexes contain p50 and p65 subunits.

Figure 3.
Results of electrophoretic mobility shift assay for NF-κB activity in the kidney after systemic infusion of AngII. Rats were treated with AngII (50 ng/kg/minute) for 24, 48, and 72 hours, and 7 days. Protein extracts were collected and used for ...

We determined the renal cells involved in AngII-induced NF-κB activation in vivo by a digoxygenin-labeled NF-κB oligonucleotide that binds to nuclear active NF-κB complexes. 30 Control rats showed no nuclear staining for NF-κB (Figure 4; A, B, and C [triangle] ). In AngII-infused rats, there was an increase in positive nuclear staining, with activated NF-κB complexes located mainly in the glomeruli (mesangial, endothelial, and epithelial cells; Figure 4, D and E [triangle] ), and in tubulointerstitial areas (tubuloepithelial and mononuclear infiltrating cells; Figure 4F [triangle] ). Moreover, there was an increase in NF-κB staining in renal arteries, located in endothelial and vascular smooth muscle cells (Figure 4, H and I) [triangle] . The semiquantitative score of NF-κB staining of the different groups is shown in Figure 4J [triangle] . Competition of binding by an excess of 100-fold unlabeled NF-κB oligonucleotide, incubation with a mutant digoxigenin-labeled NF-κB (100 pmol/L), or the absence of digoxigenin-labeled NF-κB, did not show any nuclear signal, (Figure 5) [triangle] demonstrating the specificity of the binding. These controls were done in each experiment.

Figure 4.
Southwestern histochemistry in AngII-infused rats. Control animals did not present staining for NF-κB (AC). After AngII infusion for 72 hours a clear nuclear staining for NF-κB was seen in some renal structures (D–F). ...
Figure 5.
Controls of the Southwestern histochemistry. In renal sections of AngII-infused rats several controls were done of the technique. Tissue was treated as described in Materials and Methods and incubated with digoxigenin-labeled NF-κB alone (A) or ...

Treatment with AT1 and AT2 Antagonists Diminished NF-κB Activation in AngII-Infused Animals

We determined the effect of AT1 and AT2 antagonists in renal NF-κB DNA binding activity, in rats infused with AngII for 72 hours, by EMSA and Southwestern histochemistry. Both treatments partially diminished renal NF-κB activity in AngII-infused rats [losartan, 44% (inhibition versus AngII-infusion, n = 6, P < 0.05); and PD123319, 53% (n = 4, P < 0.05; EMSA)] (Figure 6) [triangle] . Neither losartan nor PD123319 alone affected renal NF-κB activity (not shown). By Southwestern histochemistry we observed that both treatments diminished nuclear NF-κB staining in the glomeruli (Figure 7, C and D) [triangle] . The effect of the AT1 blocker was mainly observed in tubuloepithelial cells (Figure 7G) [triangle] , whereas AT2 antagonist presented a marked effect on infiltrating cells (Figure 7H) [triangle] . The semiquantitative score of NF-κB staining in the glomeruli, infiltrating and tubular cells of the different groups is shown in Figure 7I [triangle] .

Figure 6.
Role of AT1 and AT2 receptors in AngII-induced NF-κB activation. Animals were treated for 24 hours with the AT antagonists losartan and PD123319, and then infused with AngII for 72 hours A: Representative EMSA experiment that shows three different ...
Figure 7.
Effect of AT1 and AT2 antagonists on the glomeruli and tubulointerstitial areas of AngII-infused rats. [triangle] shows a representative Southwestern experiment of an animal from each group: control (A and E), AngII-infusion (B and F), treatment with ...

AngII Infusion Activates AP-1 Transcription Factor through AT1 in the Kidney

In renal cortex from AngII-infused rats there was an increase in AP-1 DNA-binding activity at 72 hours (2.6-fold versus control, n = 8, P < 0.05) decreasing after 7 days (Figure 8, A and B) [triangle] . By Southwestern histochemistry we observed that AngII-infused rats for 72 hours presented positive nuclear staining for AP-1 in glomeruli and tubulointerstitial areas (Figure 8C) [triangle] . The specificity of the binding was evaluated by competition experiments (not shown). Treatment with AT1 antagonist blocked the AngII effect on renal AP-1 binding activity (90% inhibition versus AngII-Infusion, n = 4, P < 0.05, EMSA), whereas AT2 antagonist did not have any significant effect (Figure 9) [triangle] .

Figure 8.
Systemic infusion of AngII activates renal AP-1 activity. Rats were treated with AngII for 24, 48, and 72 hours, and 7 days. Protein extracts were collected and used for gel shift assays with the AP-1 probe. A: Representative EMSA experiment that shows ...
Figure 9.
AngII-infusion activates renal AP-1 through AT1. Animals were pretreated for 24 hours with the AT antagonists losartan and PD123319, and infused with AngII for 72 hours A: Representative EMSA experiment that shows three different animals from each group. ...

Localization of AT2 in the Kidney

Many investigators have demonstrated the presence of AT1 in the adult kidney and in cultured renal cells. 1,21,32 However, there is still some controversial data about renal AT2. 9,21,24,33,34 For this reason, we investigated the presence of AT2 in the kidney, and in cultured renal cells by immunohistochemistry and Western blot (protein levels) and RT-PCR (gene expression). In renal sections of control rats, there was a positive immunostaining for AT2 located mainly in tubuloepithelial cells and, to a lesser extent, in resident glomerular cells (Figure 10A, a and b) [triangle] . Moreover, in rats with immune complex nephritis, which presented an activation of the local RAS, 31 a strong glomerular staining with the anti-AT2 antibody was observed (Figure 10A, c) [triangle] . Sections were incubated in the absence of primary antibody, as a negative control of the technique (Figure 10A, d) [triangle] . When total RNA from renal cortex was analyzed by RT-PCR, a band corresponding to the AT2 mRNA was observed (Figure 10B) [triangle] . AT2 was also detected in cultured mesangial cells from normotensive Wistar rats, but not from hypertensive rats, 34 in rat glomerular endothelial cells 9 and rabbit tubuloepithelial cells. 33 Murine tubuloepithelial cells (MCT) were incubated for 48 hours in RPMI without serum. Total proteins were analyzed by Western blot and a band of 44 kd of apparent molecular weight corresponding to the predicted size was detected (Figure 10C) [triangle] . These cells also expressed AT2 mRNA (Figure 10B) [triangle] . All these data are in agreement with previous studies showing detectable levels of AT2 in the kidney in normal and pathological conditions.

Figure 10.
Demonstration of AT2 in the kidney. A: Samples of renal tissue were incubated with an anti-AT2 antibody and stained with immunoperoxidase. [triangle] shows the presence of AT2 in control animals. As a positive control we studied a nephritic animal, and ...

AngII Activates NF-κB in Cultured Renal Cells

We performed in vitro studies to further demonstrate that the in vivo AngII effect on NF-κB could be because of a direct, nonhemodynamic, action. We have previously demonstrated that AngII activates NF-κB in cultured glomerular mesangial cells. 3 However, whether AngII regulated NF-κB activity in tubuloepithelial cells has not been evaluated. For this purpose, we used MCT cells that possess AT1 2 and AT2 (Figure 10) [triangle] .

In growth-arrested MCT AngII augmented NF-κB DNA-binding activity, being maximal with 10−9 mol/L after 30 minutes (3.1-fold versus control, n = 7, P < 0.05) and declining at 1 hour (Figure 11B) [triangle] . AngII also increased AP-1 DNA binding in MCT (Figure 11B) [triangle] , showing a similar response to that in mesangial cells. 32 To investigate the receptor subtype involved in AngII-induced NF-κB and AP-1 activation growth-arrested MCT were preincubated for 30 minutes with losartan or PD123319 (range 10−5 to 10−7 mol/L), and then stimulated with 10−9 mol/L AngII for an additional 30 minutes. The AT1 antagonist diminished in a dose-dependent manner the AngII-induced NF-κB binding activity, with a maximal inhibitory effect at 10−5 mol/L (79% versus AngII alone, n = 6, P < 0.05) (Figure 11A) [triangle] , whereas the AT2 antagonist only caused a slight diminution at 10−5 mol/L (35% versus AngII alone, n = 6) (Figure 11A) [triangle] . By contrast, only losartan blocked AngII-induced AP-1 binding activity (Figure 11B) [triangle] . All these data suggest that in cultured tubuloepithelial cells AngII activated NF-κB and AP-1 DNA binding mainly by AT1, similar to that observed in vivo in tubulointerstitial areas.

Figure 11.
In vitro studies. Effect of AngII in NF-κB (A) and AP-1 (B) DNA binding in murine tubuloepithelial cells (MCT). Resting MCT cells were treated for increasing times with 10−9 mol/L AngII. After the incubation period, nuclear extracts were ...

Previous studies have demonstrated that AngII regulates NF-κB DNA binding activity in human mononuclear cells. 13,35 These cells possess all of the components of the RAS, including AT1 and AT2 receptors. 36 In human U937 mononuclear cells, pretreatment with AT1 or AT2 antagonists (10−5 to 10−7 mol/L) diminished in a dose-dependent manner the AngII-induced NF-κB DNA binding activity (Figure 11C) [triangle] , suggesting that both receptors are involved in the NF-κB activation caused by AngII in mononuclear cells.


In this study we have found that systemic AngII infusion into rats for 72 hours activated the transcription factors NF-κB and AP-1 in the kidney being related to inflammatory cell infiltration and tubular damage. Elevated tissular NF-κB and AP-1 has been observed in certain pathological conditions, associated to activated RAS, including experimental and human glomerulonephritis. 3,14-17,37-39 Blockade of NF-κB reduced renal damage. 17 ACE inhibitors also diminished renal NF-κB activity in experimental models of renal injury, associated or not with hypertension, 3,16 suggesting that NF-κB regulation maybe be a therapeutical target in kidney diseases. Our data provide the first in vivo evidence of NF-κB activation by AngII, and identify the cell-specific localization of NF-κB DNA binding. Thus, in AngII-infused rats a positive NF-κB staining was observed in both resident renal cells and infiltrating mononuclear cells. Activated NF-κB complexes were located mainly in the glomeruli (mesangial, endothelial, and epithelial cells), tubuloepithelial cells, and renal arteries (endothelial and vascular smooth muscle cells). Previous studies, besides ours, have shown that AngII activated NF-κB in cultured cells, including glomerular mesangial cells. 3,13,35,40 In the present study, we have also found that in cultured tubuloepithelial cells, AngII caused a rapid and transient, dose-dependent increase in NF-κB DNA binding activity, with a similar potency to that of inflammatory cytokines. Although in AngII-infused rats there was a slight increase in systolic blood pressure (around 20 mmHg), the in vitro studies further demonstrate a direct, nonpressure-related AngII effect on the regulation of NF-κB activity in the kidney.

The potential role of AngII in the inflammatory response is a new and active field of investigation. AngII is involved in the pathogenesis of immune-mediated renal diseases. 3,41,42 We have found that AngII infusion causes inflammatory cell infiltration in the glomeruli and markedly in the interstitium associated with areas of focal inflammation, as previously reported. 5,9 Several data support the idea of an important role of AngII in the inflammatory process. AngII causes monocyte chemotaxis and adhesion to mesangial and endothelial cells 43-45 and NF-κB activation. 3,35 We have observed in AngII-infused rats that the infiltrating inflammatory cells exhibited activated NF-κB complexes. Resident renal cells also respond to AngII stimulation with activation of NF-κB and overexpression of related genes, such as MCP-1 and RANTES, 3,9 that could be responsible for monocyte infiltration in the kidney. All these data suggest that the effect of AngII on inflammatory cell recruitment could be direct, through activation of mononuclear cells, and indirect, via chemokine production by renal cells, both processes mediated by NF-κB activation. A common feature of all stages of atherosclerosis is inflammation of the vessel wall. Activation of NF-κB has been observed in atherosclerotic lesions, 46 and in cultured vascular smooth muscle and endothelial cells stimulated with AngII. 13,40 We have found that AngII-infusion activates NF-κB in renal arteries, suggesting a more general feature not only reduced to renal parenchyma. On the whole, our in vivo data support the new view of AngII as a proinflammatory mediator.

The importance of AngII receptors in vivo has been demonstrated by treatment with specific receptor antagonists. For example, AT1 participates in AngII-induced hypertension, cardiac hypertrophy, and extracellular matrix accumulation; 27-29,47 whereas AT2 mediates endothelium-dependent vasodilatation, 21 renal NO production 48 and its role in trophic effects on vascular smooth muscle cells is controversial. 27-29 The receptor subtype involved in renal injury is not completely defined. AT1 antagonists are currently used in the treatment of hypertension and proteinuria in patients with diabetic nephropathy. 49 In models of renal injury, AT1 antagonists decrease proteinuria, matrix accumulation, and production of growth factors, such as TGF-β. 21,50,51 The information provided by AT2 blockers and AT2 knockout mice supports an important role for the AT2 in the physiopathology of the kidney. 21,52 AT2 might participate in blood pressure control, cGMP production in response to sodium depletion, in natriuretic response via bradykinin/NO, and in renal prostanoid production and metabolism. 21,48,52,53 Unilateral obstruction in the knockout mice for the AT2 gene caused accelerated renal interstitial fibrosis and collagen deposition. 54 In AngII-infused rats we have found that treatment with the AT1 antagonist losartan restored blood pressure and improved tubular damage, whereas administration of the AT2 blocker PD123319 decreased inflammatory cell infiltration. To further investigate the molecular mechanism of AngII-induced renal injury associated to each receptor activation, we evaluated tissue levels and distribution of transcription factors. In AngII-infused animals, both AT1 and AT2 antagonists decreased AngII-increased renal NF-κB activity, whereas only AT1 blocker decreased renal AP-1 activity. Some divergences in cellular distribution of NF-κB activated cells were observed in response to each receptor antagonist. Both antagonists decreased NF-κB-positive immunostaining in the glomeruli. Losartan markedly diminished NF-κB in tubular cells, and PD123319 did so mainly in inflammatory cells. In addition, AngII increased NF-κB and AP-1 DNA binding activity mainly by AT1 in cultured tubuloepithelial cells, and activated NF-κB via both AT1 and AT2 in mononuclear cells.

One important finding of the present study is that the potential role of AT2 in the renal inflammatory process may be mediated by NF-κB activation. Thus, in AngII-infused rats, the AT2 blocker diminished both mononuclear infiltration and NF-κB DNA binding activity in inflammatory cells. Several experimental data support our hypothesis. In anti-thymocyte serum-induced nephritis two AT1 antagonists caused a significant, but not a total reduction, in MCP-1, a chemokine under NF-κB control, and reduced glomerular macrophages/monocytes infiltration only around 30 to 50%. 55 In the model of ureteral obstruction nephropathy, monocyte/macrophage infiltration was reduced by ACE inhibitors, but not by AT1 antagonists. 50,56,57 In this model, both AT1 and AT2 antagonists partially diminished NF-κB activity. 58 ACE inhibitors diminished the renal activity of NF-κB and the expression of NF-κB-regulated genes, such as MCP-1 and the adhesion molecule VCAM-1, 3,16,50 associated with the decrease in renal monocyte infiltration. In AngII-infused rats AT2, but not AT1 antagonists blocked glomerular monocyte infiltration and the expression of RANTES, 9 another NF-κB controlled chemokine. From these data, we could hypothesize that differences in renal monocyte recruitment between ACE inhibitors and AT1 blockers could be because of the action of AngII via AT2/NF-κB pathway, and show a potential clinically important unresolved question, that needs to be addressed in human diseases. In cultured cells, AngII via AT1/NF-κB pathway up-regulates some genes, such as interleukin-6, VCAM-1, MCP-1, and angiotensinogen. 59-62 In vascular smooth muscle cells, AngII increased gene and transactivated a NF-κB-driven VCAM-1 promoter through AT1. 59 Both AT1 and AT2 mediate AngII-induced NF-κB DNA binding and transcription of a NF-κB reporter gene. 62 Recently, we have unraveled some of the intracellular signals elicited by AT1 and AT2. The potential mechanism of AT1/NF-κB/gene regulation could depend on redox-sensitive signals and activation of protein tyrosine kinases and mitogen-activated protein, as occurs with proinflammatory cytokines, whereas the AT2/NF-κB pathway seems to be mediated by ceramide production. 62 All these data suggest that AngII could regulate a great variety of pathological genes through NF-κB activation via AT1 and/or AT2, although the gene and receptor involved could be specific for each tissue or pathological condition.

Another important finding is the effect of AT1 antagonist in AngII-induced renal damage. Losartan restored blood pressure, improved tubular damage, and decreased renal AP-1 activity. Interestingly, the effect of losartan on NF-κB activity was mainly located in tubular cells. Many studies have demonstrated that the renal protection caused by ACE inhibitors or AT1 antagonists are not only because of blood pressure control, but also to blockade of tissue RAS, in particular to the cellular actions of AngII. 1,2 ACE inhibitors and AT1 antagonists diminished profibrotic genes in experimental nephritis associated or not to hypertension 1,2,31,50,51 . In AngII-infused rats, losartan diminished AngII-induced aortic fibronectin by a nonpressure-mediated mechanism. 63 We have observed that in cultured tubuloepithelial cells AngII, via AT1, activated NF-κB and AP-1. Although a limitation of our in vivo studies is that we cannot clearly dissociate between direct/pressure effect, our in vitro data support the idea that the beneficial effect of AT1 antagonist could be attributed to a direct AngII/AT1 action in tubular cells. In cultured renal cells, AT1 regulates cell growth, matrix production, and the induction of profibrotic genes. 1,2,8,32 Systemic AngII infusion into rats is characterized by cell proliferation and fibrosis, 4,5 that are preceded by changes in the expression of some genes that are regulated by AP-1, such as c-fos, TGF-β, and fibronectin. 4-8,57 Among these genes, TGF-β has a pivotal role in kidney diseases. In cultured renal cells, AngII increased TGF-β via AT1. 1,2,8,32 In tubuloepithelial cells, AngII causes hypertrophy by TGF-β production. 2 TGF-β is also involved in AngII-induced matrix production in cultured renal cells and in models of renal injury. 1,2,31,32,50,51,64 AP-1 also regulates genes of the extracellular matrix proteins, such as fibronectin, that are induced by AngII via AT1, 1,51,64 and diminished by ACE inhibitors and AT1 antagonists in various models of kidney injury. 31,57 Injection of AngII induced the expression of c-fos/jun via AT1 in the brain of spontaneously hypertensive rats. 65 We have observed that AngII infusion caused activation of AP-1 via AT1, suggesting that the beneficial effect of losartan treatment could be due, at least in part, to the regulation of AP-1 transcription factor. On the whole, these experimental data support the idea that losartan blocks AT1-mediated cellular AngII actions, such as gene overexpression and activation of transcription factors (AP-1 and NF-κB), and therefore ameliorates renal damage.

Although our studies have described several AngII-mediated effects, as well as the receptors involved, there are many open questions that need future research. AT1 blockade leads to free ligand (AngII) that could theoretically bind to AT2, and then exert some potential beneficial effects, including vasodilatation and antiproliferative/apoptotic responses, 21 although there is little evidence of this mechanism in the kidney. On the other hand, AT2 could exert pathological effects through the recruitment of mononuclear cells, although this point needs to be addressed in human diseases. In addition, AT1 blockade stimulates aminopeptidase A activity, 66 an enzyme that degrades AngII to AngIII, suggesting a potential increase in AngIII that could bind to AT2. 18 AngIII causes proteinuria and increases growth-related, profibrotic and proinflammatory genes. 44,67,68 Increased renal AngII production and aminopeptidase A expression have been described in pathological settings associated to tissue RAS activation, such as hypertension, diabetes mellitus, nephritis, and AngII infusion. 69,70 These data indicate that although AngII is the main effector peptide of the renin angiotensin system other components of this system, such as AngIII, could play an active role in renal injury.

Our results suggest that the effects of AngII on renal structures take place through different receptors and transcription factors. AngII participates in inflammatory cell infiltration mainly mediated by NF-κB activation via AT2, whereas tubular damage seems to occur through AP-1 by AT1. These results describe a novel signaling mechanism associated to AngII-induced renal injury, and may contribute to a better understanding of the pathological effects of this peptide in several diseases associated with activated RAS, as renal and cardiovascular disease.


We thank Dr. P. Esbrit and Y. Suzuki for the careful reading of the manuscript, and L. Gulliksen for her secretarial assistance.


Address reprint requests to Marta Ruiz-Ortega, PhD, Laboratory of Renal and Vascular Pathology, Fundación Jiménez Díaz, Avda Reyes Católicos, 2, 28040 Madrid, Spain. E-mail: .se.djf@oziurm

Supported by grants from Fondo de Investigación Sanitaria (99/0425), Comunidad de Madrid (97/084/0003 08.4/0017/2000), Ministerio de Educación (SAF 97/0055, PM 97/0085), EU Concerted Action Grant BMH 4-CT98–3631 (DG 12-SSM1), and Fundación Renal Iñigo Alvarez de Toledo. O.L is a fellow of FIS.

M. R.-O. and O. L. contributed equally to this work.


1. Egido J: Vasoactive hormones and renal sclerosis. Kidney Int 1996, 49:578-597 [PubMed]
2. Wolf G, Neilson EG: Angiotensin II as a renal growth factor. J Am Soc Nephrol 1993, 3:1531-1540 [PubMed]
3. Ruiz-Ortega M, Bustos C, Hernández-Presa MA, Lorenzo O, Plaza JJ, Egido J: Angiotensin II participates in mononuclear cell recruitment in the kidney through nuclear factor-kappa B activation and monocyte chemoattractant protein-1 gene expression. J Immunol 1998, 161:430-439 [PubMed]
4. Kim S, Iwao H: Molecular and cellular mechanisms of angiotensin II-mediated cardiovascular and renal diseases. Pharmacol Rev 2000, 52:11-34 [PubMed]
5. Johnson RJ, Alpers CE, Yoshimura A, Lombardi D, Pritzl P, Floege J, Schwartz S: Renal injury from angiotensin II-mediated hypertension. Hypertension 1994, 19:464-474 [PubMed]
6. Miller PL, Rennke HG, Meyer TW: Glomerular hypertrophy accelerates hypertensive glomerular injury in rats. Am J Physiol 1991, 261:F459-F465 [PubMed]
7. Crawford DC, Chobanian AV, Brecher P: Angiotensin II induces fibronectin expression associated with cardiac fibrosis in the rat. Circ Res 1994, 74:727-739 [PubMed]
8. Kagami S, Border WA, Miller DE, Noble NA: Angiotensin II stimulates extracellular matrix protein synthesis through induction of transforming growth factor-β expression in rat glomerular mesangial cells. J Clin Invest 1994, 93:2431-2437 [PMC free article] [PubMed]
9. Wolf G, Ziyadeh FN, Thaiss F, Tomaszewiski J, Caron RJ, Wenzel U, Zahner G, Helmchen U, Stahl RAK: Angiontensin II stimulates expression of the chemokine RANTES in rat glomerular endothelial cells. Role of the Angiotensin type 2 receptor. J Clin Invest 1997, 100:1047-1058 [PMC free article] [PubMed]
10. Blume A, Herdegen T, Unger T: Angiotensin peptides and inducible transcription factors. J Mol Med 1999, 77:339-357 [PubMed]
11. Marrero MB, Schieffer B, Paxton WG, Heerdt L, Berk BC, Delafontaine P, Bernstein KE: Direct stimulation of Jak/STAT pathway by the angiotensin II AT1 receptor. Nature 1995, 375:247-250 [PubMed]
12. Nahman NS, Rothe KL, Falkenhain ME, Frazer KM, D’Acio LE, Madia JD, Leonhart KL, Kronenberg JC, Stauch DA: Angiotensin II induction of fibronectin biosynthesis in cultured human mesangial cells: association with CREB transcription factor activation. J Lab Clin Med 1996, 127:599-611 [PubMed]
13. Hernández-Presa M, Bustos C, Ortego M, Tuñón J, Ruiz-Ortega M, Egido J: Angiotensin converting enzyme inhibition prevents arterial NF-κB activation, MCP-1 expression and macrophage infiltration in a rabbit model of early accelerated atherosclerosis. Circulation 1997, 95:1532-1541 [PubMed]
14. Chen F, Castranova V, Shi X, Demers LM: New insights into the role of nuclear factor-kappaB, a ubiquitous transcription factor in the initiation of diseases. Clin Chem 1999, 45:7-17 [PubMed]
15. Karin M, Liu Z, Zandi E: AP-1 function and regulation. Curr Opin Cell Biol 1997, 9:240-249 [PubMed]
16. Morrissey JJ, Klahr S: Rapid communication: enalapril decreases nuclear factor kappa B activation in the kidney with ureteral obstruction. Kidney Int 1997, 52:926-933 [PubMed]
17. Muller DN, Dechend R, Mervaala EM, Park JK, Schmidt F, Fiebeler A, Theuer J, Breu V, Ganten D, Haller H, Luft FC: NF-kappaB inhibition ameliorates angiotensin II-induced inflammatory damage in rats. Hypertension 2000, 35:193-201 [PubMed]
18. Timmermans PB, Wong PC, Chiu AT, Herblin WF, Benfield P, Carini DJ, Lee RJ, Wexler RW, Saye JAM, Smith RD: Angiotensin II receptors and angiotensin II receptor antagonist. Pharmacol Rev 1993, 45:205-251 [PubMed]
19. Chung O, Kuhl H, Stoll M, Unger T: Physiological and pharmacological implications of AT1 versus AT2 receptors. Kidney Int 1998, 67:S95-S99 [PubMed]
20. Bernstein KE, Alexander W: Counterpoint: molecular analysis of the angiotensin II receptor. Endocr Rev 1992, 13:381-386 [PubMed]
21. Matsubara H: Pathophysiological role of Angiotensin II type 2 receptor in cardiovascular and renal diseases. Circ Res 1998, 83:1182-1191 [PubMed]
22. Lo M, Liu KL, Lantelme P, Sassard J: Subtype 2 of angiotensin II receptors controls pressure-natriuresis in rats. J Clin Invest 1995, 95:1394-1397 [PMC free article] [PubMed]
23. Ohkubo N, Matsubara H, Nozawa Y, Mori Y, Murasawa S, Kijima K, Maruyama K, Masaki H, Tsumi Y, Shibazaki Y, Iwasaka T, Inada M: Angiotensin type 2 receptors are reexpressed by cardiac fibroblasts from failing myopathic hamster hearts and inhibit cell growth and fibrillar collagen metabolism. Circulation 1997, 96:3954-3962 [PubMed]
24. Ozono R, Wang ZQ, Moore AF, Inagami T, Siragy HM, Carey RM: Expression of the subtype 2 angiotensin (AT2) receptor protein in rat kidney. Hypertension 1997, 30:1238-1246 [PubMed]
25. Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999, 96:6506-6510 [PMC free article] [PubMed]
26. Macari D, Whitebread S, Cumin F, De Gasparo M, Levens N: Renal actions of the angiotensin AT2 receptor ligands CGP 42112 and PD 123319 after blockade of the renin-angiotensin system. Eur J Pharmacol 1994, 259:27-36 [PubMed]
27. Li JS, Touyz RM, Schiffrin EL: Effects of AT1 and AT2 angiotensin receptor antagonists in angiotensin II-infused rats. Hypertension 1998, 31:487-492 [PubMed]
28. Sabri A, Levy BI, Poitevin P, Caputo L, Faggin E, Marotte F, Rappaport L, Samuel JL: Differential roles of AT1 and AT2 receptor subtypes in vascular trophic changes in response to stimulation with angiotensin II. Arterioscler Thromb Vasc Biol 1997, 17:257-264 [PubMed]
29. Levy BI, Bennessiano J, Henrion D, Caputo L, Heymes D, Caputo L, Duriez M, Poitevin P, Samuel JL: Chronic blockade of AT2-subtype receptors prevents the effect of angiotensin II on the rat vascular structure. J Clin Invest 1996, 98:418-425 [PMC free article] [PubMed]
30. Hernandez-Presa MA, Gomez-Guerrerro C, Egido J: In situ nonradioactive detection of nuclear factors in paraffin sections by Southwestern histochemistry. Kidney Int 1996, 49:578-581 [PubMed]
31. Ruiz-Ortega M, González S, Seron D, Condom E, Bustos C, Largo R, González E, Egido J: ACE inhibition reduces proteinuria, glomerular lesions and extracellular matrix production in a normotensive rat model of immune complex nephritis. Kidney Int 1995, 48:1778-1791 [PubMed]
32. Ruiz-Ortega M, Egido J: Angiotensin II modulates cell growth-related events and synthesis of matrix proteins in renal interstitial fibroblasts. Kidney Int 1997, 52:1497-1510 [PubMed]
33. Jacobs LS, Douglas JG: Angiotensin type 2 receptor subtypes mediates phospholipase A2-dependent signaling in rabbit proximal tubular epithelial cells. Hypertension 1996, 28:663-668 [PubMed]
34. Goto M, Mukoyama M, Suga S, Matsumoto T, Nakawaga M, Ishibashi R, Kasahara M, Sugawara A, Tanaka I, Nakao K: Growth dependent induction of angiotensin II type 2 receptor in rat mesangial cells. Hypertension 1997, 30:358-362 [PubMed]
35. Kranzhofer R, Browatzki M, Schmidt J, Kubler W: Angiotensin II activates the proinflammatory transcription factor nuclear factor-kappaB in human monocytes. Biochem Biophys Res Commun 1999, 257:826-828 [PubMed]
36. Okamura A, Rakugi H, Ohishi M, Yanagitani Y, Takiuchi S, Moriguchi K, Fennessy PA, Higaki J, Ogihara T: Upregulation of renin-angiotensin system during differentiation of monocytes to macrophages. J Hypertens 1999, 17:537-545 [PubMed]
37. Sakurai H, Shigemori N, Hisada Y, Ishizuka T, Kawashima K, Sugita T: Suppression of NF-kappa B and AP-1 activation by glucocorticoids in experimental glomerulonephritis in rats: molecular mechanisms of anti-nephritic action. Biochim Biophys Acta 1997, 1362:252-262 [PubMed]
38. Ashizawa M, Miyazaki M, Koji T, Isomoto H, Ozono Y, Harada T, Yagame M, Endoh M, Kurokawa K, Sakai H, Kohno S: Expression of nuclear factor kappa B (NF-κ B) assessed by Southwestern histochemistry (SWH) is associated with renal injury in IgA nephropathy (IgAN). J Am Soc Nephrol 1999, 10:95a
39. Akurai H, Hisada Y, Ueno M, Sugiura M, Kawashima K, Sugita T: Activation of transcription factor NF-kappa B in experimental glomerulonephritis in rats. Biochim Biophys Acta 1996, 1316:132-138 [PubMed]
40. Pueyo ME, Gonzalez W, Nicoletti A, Savoie F, Arnal JF, Michel JB: Angiotensin II stimulates endothelial vascular cell adhesion molecule-1 via nuclear factor-kappaB activation induced by intracellular oxidative stress. Arterioscler Thromb Vasc Biol 2000, 20:645-651 [PubMed]
41. Hisada Y, Sugaya T, Yamanouchi M, Uchida H, Fujimura H, Sakurai H, Fukamizu A, Murakami K: Angiotensin II plays a pathogenic role in immune-mediated renal injury in mice. J Clin Invest 1999, 103:627-635 [PMC free article] [PubMed]
42. Nataraj C, Oliverio MI, Mannon RB, Manno PJ, Audoly LP, Amuchastegui CS, Ruiz P, Smithies O, Coffman TM: Angiotensin II regulates cellular immune responses through a calcineurin-dependent pathway. J Clin Invest 1999, 104:1693-1710 [PMC free article] [PubMed]
43. Hanh AW, Jonas U, Bühler FR, Resink TJ: Activation of human peripheral monocytes by angiotensin II. FEBS Lett 1994, 347:178-180 [PubMed]
44. Ruiz-Ortega M, Lorenzo O, Egido J: Angiotensin III increases monocytic chemotactic protein-1 and activates nuclear transcription factor κB and activator protein-1 in cultured mesangial and mononuclear cells. Kidney Int 2000, 57:2285-2298 [PubMed]
45. Mene P, Pugliese F, Cinotti GA: Adhesion of U-937 monocytes induces cytotoxic damage and subsequent proliferation of cultured human mesangial cells. Kidney Int 1996, 50:417-423 [PubMed]
46. Brand K, Page S, Rogler G, Bartsch A, Brandl R, Knuechel R, Page M, Kaltschmidt C, Baeuerle PA, Neumeier D: Activated transcription factor nuclear factor-kappa B is present in the atherosclerotic lesion. J Clin Invest 1996, 97:1715-1722 [PMC free article] [PubMed]
47. Sadoshima J, Izumo S: Molecular characterization of angiotensin II-induced hypertrophy of cardiac myocytes and hyperplasia of cardiac fibroblasts. Critical role of the AT1 receptor subtype. Circ Res 1993, 73:413-423 [PubMed]
48. Siragy HM, Inagami T, Ichiki T, Carey RM: Sustained hypersensitivity to angiotensin II and its mechanism in mice lacking the subtype-2 (AT2) angiotensin receptor. Proc Natl Acad Sci USA 1999, 96:6506-6510 [PMC free article] [PubMed]
49. Andersen S, Tarnow L, Rossing P, Hansen BV, Parving HH: Renoprotective effects of angiotensin II receptor blockade in type 1 diabetic patients with diabetic nephropathy. Kidney Int 2000, 57:601-606 [PubMed]
50. Ishidoya S, Morrissey J, McCracken R, Reyes A, Klahr S: Angiotensin II receptor antagonist ameliorates renal tubulointerstitial fibrosis caused by unilateral ureteral obstruction. Kidney Int 1995, 47:1285-1294 [PubMed]
51. Border WA, Noble N: Interactions of transforming growth factor-beta and angiotensin II in renal fibrosis. Hypertension 1998, 31:181-188 [PubMed]
52. Carey RM, Wang ZQ, Siragy HM: Role of the angiotensin type 2 receptor in the regulation of blood pressure and renal function. Hypertension 2000, 35:155-163 [PubMed]
53. Siragy HM, Senbonmatsu T, Ichiki T, Inagami T, Carey RM: Increased renal vasodilator prostanoids prevent hypertension in mice lacking the angiotensin subtype-2 receptor. J Clin Invest 1999, 104:181-188 [PMC free article] [PubMed]
54. Ma J, Nishimura H, Fogo A, Kon V, Inagami T, Ichikawa I: Accelerated fibrosis and collagen deposition develop in the renal interstitium of angiotensin type 2 receptor null mutant mice during ureteral obstruction. Kidney Int 1998, 53:937-944 [PubMed]
55. Wolf G, Schneider A, Helmchen UM, Stahl RA: AT1-receptor antagonist abolish glomerular MCP-1 expression in a model of mesangial proliferative glomerulonephritis. Exp Nephrol 1998, 6:112-120 [PubMed]
56. Morrissey JJ, Klahr S: Differential effects of ACE and AT1 receptor inhibition on chemoattractant and adhesion molecule synthesis. Am J Physiol 1998, 274:F580-F586 [PubMed]
57. Wu LL, Cox A, Roe CJ, Dziadek M, Cooper ME, Gilbert RE: Transforming growth factor β1 and renal injury following subtotal nephrectomy in the rat: role of the renin-angiotensin system. Kidney Int 1997, 51:1555-1567 [PubMed]
58. Klahr S, Morrissey JJ: Comparative study of ACE inhibitors and angiotensin II receptor antagonists in interstitial scarring. Kidney Int 1997, 63:S111-S114 [PubMed]
59. Tummala PE, Chen XL, Sundell CL, Laursen JB, Hammes CP, Alexander RW, Harrison DG, Medford RM: Angiotensin II induces vascular cell adhesion molecule-1 expression in rat vasculature: a potential link between the renin-angiotensin system and atherosclerosis. Circulation 1999, 100:1223-1229 [PubMed]
60. Moriyama T, Fujibayashi M, Fujiwara Y, Kaneto T, Xia C, Kamada I, Ando A, Ueda N: Angiotensin II stimulates interleukin-6 release from cultured mouse mesangial cells. J Am Soc Nephrol 1995, 6:95-101 [PubMed]
61. Han Y, Runge MS, Brasier AR: Angiotensin II induces interleukin-6 transcription in vascular smooth muscle cells through pleiotropic activation of nuclear factor-kappa B transcription factors. Circ Res 1999, 84:695-703 [PubMed]
62. Ruiz-Ortega M, Lorenzo O, Ruperez M, König S, Wittig B, Egido J: Angiotensin II activates nuclear transcription factor κB through AT1 and AT2 receptors in cultured vascular smooth muscle cells. Molecular mechanisms. Circ Res 2000, 23:1266-1272 [PubMed]
63. Himeno H, Crawford DC, Hosoi M, Chobanian AV, Brecher P: Angiotensin II alters aortic fibronectin independently of hypertension. Hypertension 1994, 23:823-826 [PubMed]
64. Kim S, Iwao H: Involvement of angiotensin II in cardiovascular and renal injury: effects of an AT1-receptor antagonist on gene expression and the cellular phenotype. J Hypertens 1997, 15:S3-S7 [PubMed]
65. Blume A, Lebrun CJ, Herdegen T, Bravo R, Linz W, Mollenhoff E, Unger T: Increased brain transcription factor expression by angiotensin in genetic hypertension. Hypertension 1997, 29:592-598 [PubMed]
66. Prieto I, Martinez JM, Hermoso F, Ramirez MJ, Vargas F, De Gasparo M, Alba F, Ramirez M: Oral administration of losartan influences aminopeptidase activity in the frontal cortex. Eur Neuropsychopharmacol 2000, 10:279-282 [PubMed]
67. Terui J, Tamoto K, Sudo J: Proteinuric potentials of angiotensin II, [des-Asp1]-angiotensin II, and [des-Asp1, des-Arg2]-angiotensin II in rats. Biol Pharm Bull 1994, 17:1516-1518 [PubMed]
68. Ruiz-Ortega M, Lorenzo O, Egido J: Angiotensin III upregulates genes involved in kidney damage in cultured mesangial cells and renal interstitial fibroblast. Kidney Int 1998, 54:S41-S45 [PubMed]
69. Wolf G, Thaiss F, Mullaer E, Disser M, Pooth R, Zahner G, Sthal RKA: Glomerular mRNA expression of angiotensinase A after renal ablation. Exp Nephrol 1995, 3:240-248 [PubMed]
70. Thaiss F, Wolf G, Assad N, Zahner G, Sthal RKA: Angiotensinase A gene expression and activity in isolated glomeruli of diabetic rats. Diabetologia 1996, 39:275-280 [PubMed]

Articles from The American Journal of Pathology are provided here courtesy of American Society for Investigative Pathology
PubReader format: click here to try


Related citations in PubMed

See reviews...See all...

Cited by other articles in PMC

See all...


  • Compound
    PubChem Compound links
  • MedGen
    Related information in MedGen
  • PubMed
    PubMed citations for these articles
  • Substance
    PubChem Substance links

Recent Activity

Your browsing activity is empty.

Activity recording is turned off.

Turn recording back on

See more...